How does parental history of atopic disease predict the risk of atopic dermatitis in a child? A systematic review and meta-analysis

Ravn, Nina Haarup; Halling, Anne‐Sofie; Berkowitz, Aviva G.; Rinnov, Maria Rasmussen; Silverberg, Jonathan I.; Egeberg, Alexander; Thyssen, Jacob P.

doi:10.1016/j.jaci.2019.12.899

Cited by 52 publications

(49 citation statements)

References 248 publications

(197 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Together with our study findings, maternal inflammation, 24 maternal microbiome, 25 parental history of atopic disease, 26 It was already shown that maternal IgG and allergens can cross through the placenta, influencing the child's immune system. 22,23 Yet, the linkage between cord blood levels of maternal immunoglobulins to child's atopy and allergy remains unclear.…”

Section: Discussionsupporting

confidence: 85%

“…During pregnancy, the maturation of the embryonal immune system can be altered by different maternal conditions and exposures, which results in allergic or other immunological diseases later in life. Together with our study findings, maternal inflammation, 24 maternal microbiome, 25 parental history of atopic disease, 26 and maternal diet during pregnancy 27 have all been associated with childhood allergic dermatological conditions such as eczema and atopic dermatitis. As drug allergy has been shown to be associated with immunological intolerance, maternal known drug allergy may affect the developing fetal immune system, resulting in dermatological and allergic morbidity later during childhood.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Maternal known drug allergy and long‐term dermatological morbidity of the offspring

Noy

Wainstock

Leibson

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

Drug allergy is associated with adverse short‐term perinatal outcomes such as caesarian delivery and preterm delivery. The aim of the present study was to determine whether being born to a mother with known drug allergy increases the risk for long‐term dermatological morbidity of the offspring. A population‐based cohort study, comparing long‐term dermatological morbidity of offspring to mothers with and without known drug allergy, was conducted. Dermatological morbidity was assessed up to the age of 18 years according to a predefined set of ICD‐9 codes associated with hospitalization of the offspring. A Kaplan‐Meier survival curve was used to compare cumulative incidence of long‐term dermatological morbidity, and a Cox proportional hazards model was constructed to control of confounders. During the study period, 243,682 deliveries met the inclusion criteria, of them 4% (n = 9756) were of mothers with known drug allergy. Offspring born to mothers with known drug allergy had higher rates of long‐term dermatological morbidity Likewise, the cumulative incidence of long‐term dermatological morbidity was higher as compared with those without known drug allergy (Kaplan‐Meier log‐rank P = .021). Using a Cox proportional hazards model, controlling for confounders, being born to a mother with known drug allergy was found to be an independent risk factor for long‐term dermatological morbidity of the offspring (adjusted HR 1.2, 95% CI 1.03‐1.33, P = .016). Being born to a mother with known drug allergy is independently associated with higher risk for long‐term dermatological morbidity of the offspring.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 84%

Maternal known drug allergy and long‐term dermatological morbidity of the offspring

Noy

Wainstock

Leibson

et al. 2020

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…1 Nutrition, pollution, microbiome, and other environmental factors that interact with the genetic background can reshape the fetal genetics and epigenetics. 2,3 These genetic and epigenetic factors can leave long-term in uences on a patient's immunological, cardiovascular, and other systemic functioning and can lead to diseases later in life. 4,5 Many birth cohort studies have investigated the link between perinatal exposure and the outcomes of atopic diseases in an attempt to identify possible predictive biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Cord blood soluble Fas ligand linked to allergic rhinitis and lung function in seven-year-old children

Chiu

Tsai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Serum or cord blood soluble Fas ligand (FasL) has been related to asthma, allergic rhinitis, and atopic dermatitis in cross-sectional and short-term follow-up studies. However, the association of cord blood soluble FasL with long-term allergic outcomes has seldom been investigated. Thus, this study investigated the relationship between cord blood soluble FasL and long-term allergic outcomes in a follow-up birth cohort. Methods The Prediction of Allergies in Taiwanese Children birth cohort study recruited healthy newborns upon delivery. At birth, blood was collected from the umbilical cords of these children, and the cord blood soluble Fas ligand levels were measured. At the age of seven years, the allergic outcome of each child was diagnosed by pediatric allergists and pulmonologists. Tests were conducted to measure the specific immunoglobulin E, fractional exhaled nitric oxide (FeNO), and pulmonary function levels of each child. Results Cord blood soluble FasL levels were higher in 7-year-old children with allergic rhinitis (Odds ratio [OR] = 2.41, p = .012) and expiratory airway obstruction (the highest forced expiratory volume in 1 second/ forced vital capacity < 90%, OR = 2.11, p = .022). The FeNO and Dermatophagoides pteronyssinus-specific immunoglobulin E levels of 7-year-old children were positively correlated with cord blood soluble FasL levels (p = .006 and .02, respectively). Conclusions In this birth cohort, the cord blood soluble FasL levels were associated with allergic rhinitis, obstructive-type lung function, FeNO, and house dust mite sensitization in 7-year-old children. The cord blood soluble FasL level might be used as a predictor for allergic diseases in children who are 7 years old.

show abstract

“…AD causes health-related burdens associated with pruritus and poor quality of life [1]. A systematic review and meta-analysis showed that parental history of AD increased the risk of AD in the offspring (pooled odds ratio: 3.30, 95% con dence interval [CI]: 2.45-4.42) [2]. Genetically susceptible individuals of AD have a higher risk of AD.…”

Section: Introductionmentioning

confidence: 99%

Effective Prevention of Atopic Dermatitis by Applying Fam’s Baby Moisturizer Twice Daily or Once Daily Compared with 2e Moisturizer Once Daily in High-Risk Neonates: Study Protocol for A Randomized, Blinded, Parallel, Three Group, Phase II Trial (PAF Study)

Inuzuka¹,

Yamamoto‐Hanada²,

Pak³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundAtopic dermatitis (AD) is a chronic and inflammatory skin disease that commonly affects young children. AD causes health-related burdens associated with pruritus and poor quality of life. The efficacy of moisturizer application shows inconsistency on primary prevention of AD according to previous randomized, controlled trials. Which moisturizer is effective and how often moisturizer should be applied to prevent development of AD in infants remain unclear. We hypothesize that twice daily application of moisturizer using Fam’s Baby is more effective than once daily application and that a sufficient amount of moisturizer application is effective for preventing development of AD in neonates and infants. Therefore, this study aimed to examine whether applying Fam’s Baby twice daily or once daily prevents AD compared with 2e moisturizer once daily in neonates and infants with at least one parent or sibling who has had atopic dermatitis.MethodsThis study is a single-center, three-parallel group, assessor-blind, superiority, individually randomized, controlled, phase II trial. A newborn with at least one parent or sibling who has had AD is randomly assigned to application of Fam’s Baby twice daily, Fam’s Baby once daily, or 2e once daily in a 1:1:1 ratio until 32 weeks old. The primary outcome is the time to the first onset of AD during administration of the moisturizer.DiscussionThis is the first phase II randomized, controlled trial in Japan to investigate whether applying moisturizer (Fam’s Baby) twice daily or once daily can prevent the incidence of AD compared with another moisturizer (2e) once daily in high-risk neonates. In this study, we will use 2e once daily as control moisturizer to confirm the efficacy for primary prevention of AD as found in our previous trial. Evaluation of application of moisturizers for preventing AD in this study is expected to contribute to a reduction in the prevalence of AD and a reduction in health care costs. Trial registrationJapan Registry of Clinical Trials (jRCT); ID: jRCTs031200070. Registered on 20 July 2020.

show abstract

How does parental history of atopic disease predict the risk of atopic dermatitis in a child? A systematic review and meta-analysis

Cited by 52 publications

References 248 publications

Maternal known drug allergy and long‐term dermatological morbidity of the offspring

Maternal known drug allergy and long‐term dermatological morbidity of the offspring

Cord blood soluble Fas ligand linked to allergic rhinitis and lung function in seven-year-old children

Effective Prevention of Atopic Dermatitis by Applying Fam’s Baby Moisturizer Twice Daily or Once Daily Compared with 2e Moisturizer Once Daily in High-Risk Neonates: Study Protocol for A Randomized, Blinded, Parallel, Three Group, Phase II Trial (PAF Study)

Contact Info

Product

Resources

About